Through the development of a highly sensitive fourth‐generation single molecule array, SiMoA (Quanterix Corporation, Billerica, MA), for detection in blood,27, 28 NfL has been reported in different neurodegenerative diseases as a blood‐based biomarker correlating with disease status, progression, and outcomes in different neurological diseases.23, 28. This evidence concerns the gene NEFL and neurodegenerative disease.